The UK Health Security Agency (UKHSA) has released a new tool that will help research and development efforts of diagnostics, vaccines, and treatments for pathogens that pose the greatest risk to public health.
An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing immense pressure on our societies. A shift to a preventative approach is necessary for the efficiency and sustainability of our healthcare systems. Central to this shift is the often-underutilized tool of life-course immunization.
Researchers have made a new discovery in the fight against malaria. The study, recently published in Science, identified a new class of antibodies targeting a previously unexplored malaria parasite region.
In the possible event of a pandemic, the UK has secured 5 million doses of an H5 influenza vaccine to stay one step ahead of the avian influenza virus.
Dr Ayoade Alakija, humanitarian leader, WHO Special Envoy for the ACT-Accelerator, Chair of FIND and Co-Chair of the G7 Impact Investment Initiative on Global Health, outlines the negative effects of vaccine nationalism and emphasizes the importance of countries collaborating to enhance preparedness and medical countermeasures in the face of public health threats.
Sian Williams, Senior Policy Adviser for Child Health at the UK Committee for UNICEF (UNICEF UK), explains the barriers to childhood vaccination and the health consequences of missed immunisations.
Milena Angelova, EESC member and Rapporteur for the EESC opinion on Vaccine-preventable cancers, highlights the vital role of civil society in eradicating them.
Dr Nenad Miljković, President-elect of the European Association of Hospital Pharmacists (EAHP), outlines the critical role of cold chain management in maintaining the efficacy and safety of vaccines.
Open Access Government discusses the prevalence of neglected tropical diseases, including barriers to awareness and the need to scale up effective interventions.
Wales is set to introduce a vaccination program aimed at protecting vulnerable populations from a common but potentially severe respiratory infection known as Respiratory Syncytial Virus (RSV).
Researchers from the Wellcome Sanger Institute, University College London (UCL), and Imperial College London have revealed insights into why some people remain unscathed despite exposure to SARS-CoV-2, the virus responsible for COVID-19.
An HIV vaccine candidate developed at the Duke Human Vaccine Institute has demonstrated the ability to trigger low levels of a rare type of neutralising antibodies (bnAbs) in a small group of participants.
